The Biotechnology Industry
2.1K views | +1 today
Follow
The Biotechnology Industry
All about the Biotechnology Industry
Your new post is loading...
Your new post is loading...
Scooped by Thibaud Guymard
Scoop.it!

Britain's biotech stars fade away

Britain's biotech stars fade away | The Biotechnology Industry | Scoop.it
Analysts declare death of all-or-nothing approach after more than a third of listed biotechs go bust in three years...

 

It sounds like a case study for Eric Schmidt's view that Britain squanders its innovations in science and engineering. The biotech industry, where medicines are developed from scratch, was once seen as a sector where Britain could lead the world.

 

But, despite great promise, some of the brightest stars in drug development – such as lung cancer firm Antisoma – have failed and faded away to leave a rump of companies in the £5bn sector.

 

"The small-cap healthcare sector has had quite a rough ride over the last few years," said Chris Spooner, chief executive of Sinclair which recently merged with IS Pharma and specialises in dermatology and wound-care. Perhaps supporting the Google chairman's theory, he said companies have encountered "problems with technology or management".

more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Innovative China: Policies for the Future

Innovative China: Policies for the Future | The Biotechnology Industry | Scoop.it
As the second largest and fastest growing market for biotechnology products, China needs no introduction. The opportunity to heal, fuel, and feed 1.3 billion global citizens stands in clear contrast with the regulatory, financial, and political frameworks that present challenges to the life science industry’s external access to the evolving Chinese market. On Tuesday at the 2011 BIO International Convention, a panel discussion titled “Innovative China: Policies for the Future” addressed the future of the biotechnology industry in China, and the regulatory structure.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

FDA Tries to Address Some Concerns Over Nanotech in Biotech

FDA Tries to Address Some Concerns Over Nanotech in Biotech | The Biotechnology Industry | Scoop.it
The naked eye cannot see particles that are a billionth of a meter, or a nanometer. Yet the FDA is trying to get its arms around them, so to speak, in hopes of defining for biotechnology companies and others whether FDA-regulated products contain nanomaterials or otherwise involve the application of nanotechnology.

FDA recently issued a draft guidance titled “Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology” and has launched a 60-day comment period on it. “The guidance is intended to help industry identify when they should consider potential implications for regulatory status, safety, effectiveness, or public health impact that may arise with the application of nanotechnology in FDA-regulated products,” Jeff Ventura, an FDA spokesman, told GEN.

In the draft guidance, FDA stated that...
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

The Man Behind The First Cancer-Treating Vaccine On The FDA And Innovation

The Man Behind The First Cancer-Treating Vaccine On The FDA And Innovation | The Biotechnology Industry | Scoop.it
For two decades, researchers hoped it might be possible to create a vaccine that teaches the body’s sentries, called dendritic cells, to recognize cancer, and then spur the immune system’s infantry, the T-cells, to attack the tumor. But every drug company that tried the approach failed — until last year. That’s when Seattle-based Dendreon got approval from the Food and Drug Administration to market its vaccine, Provenge, as a treatment for prostate cancer that has spread but is not causing symptoms like bone pain.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Competition in Tissue Engineering and Cell Therapy

Competition in Tissue Engineering and Cell Therapy | The Biotechnology Industry | Scoop.it
Competition in the field of tissue engineering and cell therapy is intense, whether it be attracting top scientists, obtaining licenses to university-owned patents, being the first to reach market with a particular technology, obtaining coveted...
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

The Rise of Backyard Biotech

The Rise of Backyard Biotech | The Biotechnology Industry | Scoop.it
Powered by social networking, file sharing, and e-mail, a new cottage industry is bringing niche drugs to market.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Biogen in talks with generic biotech partners

Biogen in talks with generic biotech partners | The Biotechnology Industry | Scoop.it
Biogen Idec Inc is discussing with several companies the possibility of forming a partnership to develop generic versions of biologic drugs known as biosimilars.Speaking...
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Indian BioTech industry to reach $10 bn mark by 2015

The Indian biotechnology sector is expected to touch the $10 billion mark by 2015 on the back of emerging opportunities across various verticals, namely biopharma, agri-biotechnology, industrial biotechnology among others.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Top 10 most innovative biotech companies

Top 10 most innovative biotech companies | The Biotechnology Industry | Scoop.it
Fast Company magazine recently came out with their list of the top 10 most innovative biotech companies. Here’s who made the cut.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Human Genome Sciences’ Watkins elected BIO chair

Human Genome Sciences’ Watkins elected BIO chair | The Biotechnology Industry | Scoop.it
Thomas Watkins, the CEO of Human Genome Sciences who led the Rockville biotech to a landmark drug approval this year, has been elected chairman of his industry’s biggest trade group during its convention in Washington, D.C.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Strangest Biotech Of All Issues Annual Report In Comic Book Form

Strangest Biotech Of All Issues Annual Report In Comic Book Form | The Biotechnology Industry | Scoop.it
There are so many ways that United Therapeutics of Rockville, Maryland, is unlike other biotech firms — from its profitability to its unique culture — that perhaps this only merits a footnote. But it is the first company that I have ever seen publish its annual report as a comic book .
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Biotechs Breathe New Life Into Health Care SPDR

Biotechs Breathe New Life Into Health Care SPDR | The Biotechnology Industry | Scoop.it
Health care firms reported stronger-than-expected Q1 results, and in a vigorous way that indicates a revaluation of the sector may be underway.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Is Pharma's Perfect Storm Biotech's Greatest Opportunity?

Many folks within pharma lament the current challenges and look back to a gilded era when blockbusters provided rivers of cash flow and supported growth based activities - both R&D and marketing.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Dealtalk: No biotech too large to buy?

Dealtalk: No biotech too large to buy? | The Biotechnology Industry | Scoop.it
No biotech company is too big to be bought, at least according to one veteran healthcare executive.David Snow, chief executive of Medco Health Solutions , sees major...
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

Generic biotech drugs part of healthcare overhaul law

Consumers could see additional savings with generic versions of expensive, cutting-edge biotechnology drugs thanks to the healthcare overhaul legislation that was signed into law last year.
more...
No comment yet.
Scooped by Thibaud Guymard
Scoop.it!

China Biotech Week in Review: Beijing Start-Up Reports 'Large' Investment from Merck

China Biotech Week in Review: Beijing Start-Up Reports 'Large' Investment from Merck | The Biotechnology Industry | Scoop.it
BeiGene, a Beijing startup that focuses on oncology drugs, announced an initial investment from Merck...
more...
No comment yet.